Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors

Mont-Saint-Guibert, Belgium – January 9, 2023 10:30pm CET / 4:30pm ET – Nyxoah SA NYXH(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), announced today that it has appointed Mr. Daniel Wildman to its board of directors as an independent director the directors^*.

Mr. Wildman is a 40-year veteran of the medical device industry. He is currently the CEO of Progenerative Medical, Inc. and a strategic advisor to several medical device and pharmaceutical companies. He is also a member of the Board of Directors of UroGen Pharma, Ltd.

Mr. Wildman spent most of his career at Johnson & Johnson (“J&J”), where he led the Digital Surgery Strategy Initiative, J&J’s DuPuy Synthes Spine franchise and J&J’s Ethicon Biosurgery division. Prior to J&J, Mr. Wildman spent ten years at Boston Scientific Corporation in various sales, marketing, operations and strategic planning positions.

Robert Taub, Chairman of the Nyxoah Board of Directors, commented, “We are delighted to welcome Mr. Wildman to the Nyxoah Board. His wealth of experience and knowledge in the medical device and pharmaceutical industries will be invaluable as Nyxoah builds out its clinical research and development and commercial strategies.”

Mr. Wildman added, “I am very impressed with the patient-centric design of Nyxoah’s Genio® hypoglossal nerve stimulation system and the benefits it can offer to people suffering from obstructive sleep apnea. As a board member, I look forward to working with Nyxoah’s leadership team to gain approval and launch Genio® in the United States.”

* Wildman Ventures LLC, represented by Mr. Daniel Wildman, has been appointed as a director. The appointment is effective immediately, subject to confirmation by the Company’s shareholders at the next general meeting.

About Nyxoah
Nyxoah is a medical technology company…